Literature DB >> 23553721

Secreted proteases of Trypanosoma brucei gambiense: possible targets for sleeping sickness control?

Géraldine Bossard1, Gérard Cuny, Anne Geiger.   

Abstract

Human African trypanosomiasis (HAT) is caused by trypanosomes of the species Trypanosoma brucei and belongs to the neglected tropical diseases. Presently, WHO has listed 36 countries as being endemic for sleeping sickness. No vaccine is available, and disease treatment is difficult and has life-threatening side effects. Therefore, there is a crucial need to search for new therapeutic targets against the parasite. Trypanosome excreted-secreted proteins could be promising targets, as the total secretome was shown to inhibit, in vitro, host dendritic cell maturation and their ability to induce lymphocytic allogenic responses. The secretome was found surprisingly rich in various proteins and unexpectedly rich in diverse peptidases, covering more than ten peptidase families or subfamilies. Given their abundance, one may speculate that they would play a genuine role not only in classical "housekeeping" tasks but also in pathogenesis. The paper reviews the deleterious role of proteases from trypanosomes, owing to their capacity to degrade host circulating or structural proteins, as well as proteic hormones, causing severe damage and preventing host immune response. In addition, proteases account for a number of drug targets, such drugs being used to treat severe diseases such AIDS. This review underlines the importance of secreted proteins and especially of secreted proteases as potential targets in HAT-fighting strategies. It points out the need to conduct further investigations on the specific role of each of these various proteases in order to identify those playing a central role in sleeping sickness and would be suitable for drug targeting.
Copyright © 2013 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Trypanosoma brucei gambiense; excreted-secreted proteins; proteases; sleeping sickness; therapeutic targets

Mesh:

Substances:

Year:  2013        PMID: 23553721     DOI: 10.1002/biof.1100

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  6 in total

1.  In vitro and in vivo evaluation of kinase and protease inhibitors against Trypanosoma evansi.

Authors:  Wangchuk Dorjee Bhutia; Snehil Gupta; Ruma Rani; Kanisht Batra; Khushboo Sethi; Sanjay Kumar; Rajender Kumar
Journal:  Vet Res Commun       Date:  2022-06-25       Impact factor: 2.459

2.  Extracellular release of two peptidases dominates generation of the trypanosome quorum-sensing signal.

Authors:  Mabel Deladem Tettey; Federico Rojas; Keith R Matthews
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

Review 3.  The silicon trypanosome: a test case of iterative model extension in systems biology.

Authors:  Fiona Achcar; Abeer Fadda; Jurgen R Haanstra; Eduard J Kerkhoven; Dong-Hyun Kim; Alejandro E Leroux; Theodore Papamarkou; Federico Rojas; Barbara M Bakker; Michael P Barrett; Christine Clayton; Mark Girolami; R Luise Krauth-Siegel; Keith R Matthews; Rainer Breitling
Journal:  Adv Microb Physiol       Date:  2014       Impact factor: 3.517

4.  Variable Surface Glycoprotein from Trypanosoma brucei Undergoes Cleavage by Matrix Metalloproteinases: An in silico Approach.

Authors:  Cláudia Jassica Gonçalves Moreno; Taffarel Torres; Marcelo Sousa Silva
Journal:  Pathogens       Date:  2019-10-08

5.  Basement membrane proteins as a substrate for efficient Trypanosoma brucei differentiation in vitro.

Authors:  Federico Rojas; Mathieu Cayla; Keith R Matthews
Journal:  PLoS Negl Trop Dis       Date:  2021-04-28

6.  Oligopeptide Signaling through TbGPR89 Drives Trypanosome Quorum Sensing.

Authors:  Federico Rojas; Eleanor Silvester; Julie Young; Rachel Milne; Mabel Tettey; Douglas R Houston; Malcolm D Walkinshaw; Irene Pérez-Pi; Manfred Auer; Helen Denton; Terry K Smith; Joanne Thompson; Keith R Matthews
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.